Effect of Bimekizumab on Symptoms and Impact of Disease in Patients with Psoriatic Arthritis over 3 Years: Results from BE ACTIVE - Sorbonne Université Access content directly
Journal Articles Rheumatology Year : 2022

Effect of Bimekizumab on Symptoms and Impact of Disease in Patients with Psoriatic Arthritis over 3 Years: Results from BE ACTIVE

Abstract

Abstract Objectives Evaluate effects of long-term bimekizumab treatment on patient-reported outcome (PRO) measures, symptoms and the impact of PsA on patients. Methods Patients with active PsA were enrolled into BE ACTIVE, a 48-week randomised controlled trial (NCT02969525). After Week 48, patients could enter a 104-week open-label extension (NCT03347110), receiving bimekizumab 160\,mg every four weeks. PRO measures assessed included arthritis pain visual analogue scale (VAS), PsA Impact of Disease (PsAID)-9, 36-Item Short Form Survey (SF-36) and HAQ-Disability Index (HAQ-DI). Results were analysed as mean (S.E.M.) changes from baseline (CfB) from Week 0 to the end of the open-label extension (3\,years) and as percentage of patients reaching patient-acceptable symptom state (PASS) for global impact (PsAID-9 total score ≤q4) and normal function (HAQ-DI total score <0.5). Non-responder imputation was applied to missing binary outcomes. Results In 206 patients (mean age 49.3\,years, 51.0% male), completion rate was high; 161 (78.2%) patients completed Week 152. Bimekizumab treatment was associated with long-term sustained improvements in pain [arthritis pain VAS CfB; Week 48: -29.9 (1.9); Week 152: -32.0 (1.9)] and fatigue [PsAID-9 fatigue CfB; -2.4 (0.2); -2.7 (0.2)]. High percentages of patients achieved acceptable symptom state (PsAID-9 PASS: 75.2%; 65.0%) and normalised function (HAQ-DI <0.5: 49.0%; 46.1%). Improvements in patient global assessment and SF-36 Physical Component Summary were also sustained. Conclusions Bimekizumab treatment was associated with long-term sustained improvements in pain and fatigue, reducing overall impact of PsA on patients. Physical function and quality of life improved up to 3\,years. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT02969525, NCT03347110.

Dates and versions

hal-03896059 , version 1 (13-12-2022)

Identifiers

Cite

Philip J Mease, Akihiko Asahina, Dafna D Gladman, Yoshiya Tanaka, William Tillett, et al.. Effect of Bimekizumab on Symptoms and Impact of Disease in Patients with Psoriatic Arthritis over 3 Years: Results from BE ACTIVE. Rheumatology, 2022, pp.keac353. ⟨10.1093/rheumatology/keac353⟩. ⟨hal-03896059⟩
16 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More